Oncology

Men with breast cancer had higher mortality than women regardless of cancer type, treatment, and access to care.

Pharmacy Times® will be on site at the 61st American Society of Hematology Annual Meeting and Exposition.

Psychological factors such as anxiety and depression can directly influence a patient’s experience with cancer-related pain.

Specialty Pharmacy Times will be on-site in San Antonio, TX, for the 2019 San Antonio Breast Cancer Symposium, taking place December 10 to 14, 2019.

It is currently uncertain to what extent interleukin inhibitors may increase the risk of serious infections and cancer in patients being treated for rheumatic diseases.

Trastuzumab-dkst (Ogivri, Mylan, Biocon), a biosimilar to trastuzumab (Herceptin, Genentech Inc.), has been launched in the US, according to an announcement from Mylan N.V. and Biocon Ltd. It is the first biosimilar approved by the FDA and recommended by the FDA Oncologic Drugs Advisory Committee.

Under a new international collaboration, the FDA has granted supplemental approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia.

Durvalumab (Imfinzi, AstraZeneca) and tremelimumab plus chemotherapy improved progression-free survival in first-line stage 4 non-small cell lung cancer.

A recent study published in CANCER indicates that for patients with both HIV and cancer, implementation of the Patient Protection and Affordable Care Act (ACA) improved insurance coverage, both in states that expanded Medicaid coverage and in states that did not.1

FDA breakthrough designation is based on data for nivolumab plus ipilimumab in a study evaluating the immuno-oncology combination in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

Rituximab-abbs (Truxima, Teva and Celltrion), has been launched in the United States with a full oncology label for non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Pegfilgrastim-bmez (Ziextenzo, Sandoz), a biosimilar to pegfilgrastim (Neulasta), is indicated to decrease the incidence of febrile neutropenia, a serious adverse effect of chemotherapy.

The largest ever trial of postoperative radiotherapy in prostate cancer shows men may be spared the procedure after surgery.

Top news of the day from across the health care landscape

Men treated with stereotactic ablative radiotherapy found to live significantly longer without any detectable disease progression compared with patients who received no additional treatment.

A study assessing melanoma cell variability indicates that identifying differences in cell states can be leveraged to improve patient outcomes.

Multiple health care organizations, including The American Hospital Association (AHA), the Institute for Safe Medication Practices (ISMP), and the American Society of Health-System Pharmacists (ASHP), have shown their full support for the MEDS Act.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Psoriasis may increase the risk of cancer incidence and cancer-related mortality in affected individuals.

Genentech has announced the results of a Phase III study which showed that atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) increased overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC).

Patients with metastatic breast cancer who receive care aligned with National Comprehensive Cancer Network guidelines experienced less financial burden than patients who received guideline-discordant treatment.

Niraparib (Zejula) received approval for patients with advanced homologous recombination deficiency-positive status ovarian cancer who have received 3 or more prior chemotherapies.

Top news of the day from across the health care landscape.

In addition to Jennifer Garner, actresses Julia Louis-Dreyfus and Christina Applegate are advocates for breast cancer, both being survivors of the disease.

Researchers note that a metabolic imbalance in some patients with cancer following treatment with nivolumab is associated with shorter survival.

Pegilodecakin in combination with pembrolizumab and nivolumab achieved measurable responses in patients with non-small cell lung cancer and kidney cancer.

Top news of the day from across the health care landscape.

After participating in a sleep-education program, 41% of participants who survived cancer had their insomnia successfully treated.